Medscape is available in 5 Language Editions – Choose your Edition here.


Idiopathic Intracranial Hypertension Treatment & Management

  • Author: Mark S Gans, MD; Chief Editor: Andrew G Lee, MD  more...
Updated: Jan 28, 2016

Approach Considerations

The treatment goal for patients with idiopathic intracranial hypertension (IIH) is to preserve optic nerve function while managing increased intracranial pressure (ICP). Medical management is multifaceted. Optic nerve function should be carefully monitored with an assessment of visual acuity, color vision, optic nerve head appearance, and perimetry. Weight control is recommended for obese patients.[60] Exogenous agents related to increased ICP should be discontinued.

Patients without visual loss most often are treated with a carbonic anhydrase inhibitor (eg, acetazolamide) to lower the ICP. While, historically, this has been the mainstay of treatment, it has now been corroborated with an NIH-funded study (Idiopathic Intracranial Hypertension Treatment Trial). In patients with severe symptoms, early visual field loss, or poor response to standard medical therapy, some clinicians utilize a short course of high-dose oral corticosteroids to temporarily postpone the need for surgical intervention.

When new visual field loss is documented, medical management should be coupled with plans for emergency surgical intervention if the visual function continues to deteriorate or does not improve immediately with corticosteroid treatment.

Visual loss in one or both of the eyes can evolve rapidly despite the best efforts to arrest the process. In this author’s experience, IIH has been a frequent cause of litigation. Almost uniformly, cases center on the delay of maximum medical and surgical management for patients who present with rapidly declining vision.

The exact time window within which vision loss can be reversed after symptomatic decline is not known. Opinions among experts in the field vary as to how rapidly and aggressively any given patient should have been treated. As a rule, it is better to err on the side of rapid intervention (ie, within hours to days) in such patients. This is a dramatic opportunity to save vision that can be easily lost. A major medicolegal pitfall is created when poor outcome is coupled with the perception of delayed treatment.

One of the standard teachings regarding this condition has been that pregnancy exacerbates or triggers the onset of symptomatic IIH. At present, however, there is little statistical evidence of a causal association between pregnancy and IIH, beyond the fact that pregnancy is common in the age group and gender that is predominantly affected by IIH.[61, 62]


Pharmacologic Therapy

Acetazolamide and furosemide

In a 2014 NIH-funded study of 165 patients with IIH and mild vision loss (the Idiopathic Intracranial Hypertension Treatment Trial), researchers found that acetazolamide treatment for six months in conjunction with a low-sodium weight-reduction diet modestly improved vision, reduced intracranial pressure, improved quality of life, and reduced papilledema. Average improvement in perimetric mean deviation (PMD) was 1.43 dB with acetazolamide and 0.71 dB with placebo. Data show that the effect of the drug was independent of weight loss.[63, 64]

Acetazolamide appears to be the most effective agent for lowering ICP. Most patients experience adequate relief of symptoms (typically, headache) with this first-line agent. The brand-name formulation Diamox appears to be better tolerated than generic acetazolamide is.

The initial dosage should be 0.5-1 g/day. Although many physicians start patients on 250 mg twice daily, others consider this dosage too low. A 500-mg oral dose of Diamox Sequels twice daily is preferred; however, some insurers only cover an oral dose of 250 mg 4 times per day. Most patients respond to a dosage of 1-2 g/day. This can be increased to 3-4 g/day, but most patients cannot tolerate the adverse effects (eg, extremity paresthesias, fatigue, metallic taste from carbonated beverages, and decreased libido) that occur at this high dosage.[2, 4]

In the event of intolerance to acetazolamide, furosemide may be used as a replacement diuretic in this group. Unfortunately, it does not appear to be as effective as acetazolamide.

Headache prophylaxis

For patients with stable visual function but inadequate headache relief with first-line pressure-lowering drugs, primary headache prophylaxis should be considered. Patients with IIH may experience headaches that have many of the features of migraine. These headaches can often be controlled with amitriptyline, propranolol, or other commonly prescribed migraine prophylaxis agents. Topiramate is also an excellent choice, in that one of its side effects is weight loss (a common association in IIH), which can help put the disease in remission.


Corticosteroids are effective in lowering ICP in patients whose IIH has an inflammatory etiology. In addition, they may be used as a supplement to acetazolamide to hasten recovery in patients who present with severe papilledema. Because of their significant adverse effects, corticosteroids should not be considered as a long-term solution for IIH patients. In addition, a rebound in the ICP may occur during the tapering of the corticosteroid dosage.[4]

Patients experiencing a progressive loss of visual field in one or both of the eyes should immediately be placed on high-dose (60-100 mg/day) oral prednisone (or an equivalent corticosteroid regimen). Digoxin and furosemide have been advocated by some investigators, but these are on the same level of effectiveness as acetazolamide and are not appropriate as sole therapy for patients who are losing vision.

If a moderately severe new visual field loss is detected on a routine office visit, and the patient is not experiencing progressive symptoms, outpatient management can continue. However, visual fields should be measured every few days or at 1- to 2-week intervals, depending on the magnitude and progression of the defect. If the visual field continues to worsen on corticosteroid treatment, the patient should be admitted for immediate surgical management.

If the patient presents with symptomatic deterioration of vision, and the examination documents worsening of visual field despite adequate standard medical therapy, the patient should be started immediately on corticosteroids, as previously outlined. The patient also should be admitted to the hospital for consideration of emergency surgical decompression. Visual field examination should be performed daily, and surgical decompression should be carried out if no improvement or further worsening is noted in the subsequent 24-48 hours.


Optic Nerve Sheath Fenestration, CSF Diversion, and Venous Sinus Stenting

Patients with IIH should be closely monitored while on medical treatment. The frequency of visits is determined by the initial state of the patient’s visual function and the response to medical treatment. Despite close follow-up care and maximum medical treatment, some patients experience deterioration of their visual function. In this situation, surgical intervention may be considered. Such intervention most often takes 1 of the following 2 general approaches:

  • Optic nerve sheath fenestration (decompression)
  • Cerebrospinal fluid (CSF) diversion (ie, via a lumboperitoneal or ventriculoperitoneal shunt)

However, intracranial venous sinus stenting has also been investigated (see below). Treatment of IIH with repeated lumbar punctures is considered to be of historic interest only.

Optic nerve sheath fenestration

The ophthalmic surgical approach to managing patients with progressive vision loss and papilledema involves cutting slits or rectangular patches in the dura surrounding the optic nerve immediately behind the globe.[65] This allows direct egress of CSF into the orbital fat, where it is absorbed into the venous circulation.

Optic nerve sheath fenestration has been demonstrated to reverse optic nerve edema and to bring about some recovery of optic nerve function. In addition, it may decrease headache in many patients. The approach to the optic nerve may be from either the medial or the lateral aspect of the orbit; each approach has its benefits and drawbacks.[66]

Although ICP typically remains elevated in these patients postoperatively, the local filtering effect of the fenestration acts as a safety valve and keeps the pressure from being transmitted to the optic nerve. Despite the general lack of an ICP-lowering effect, unilateral surgery occasionally has a bilateral curative effect on the papilledema. However, if this is not the case, the opposite nerve must undergo the same procedure.

Complications related to optic nerve sheath fenestration include the following:

  • Diplopia
  • Optic nerve injury
  • Vascular occlusion
  • Tonic pupil
  • Hemorrhage and infection (risks inherent to intraconal surgery)

Unfortunately, the procedure may not have lasting benefits. In most cases, visual function stabilizes or improves after optic nerve sheath decompression in the short run,[67] but in at least one third of cases, secondary visual decline may occur within 3-5 years and may necessitate repeat surgery or an alternative treatment; Spoor and McHenry found the long-term success rate of this operation to be only 16%.[68]

A study of optic nerve sheath fenestration performed in 41 eyes from 21 patients with vision loss from either IIH or intracranial hypertension from cerebral venous thrombosis found best-corrected visual acuity and visual field to be stabilized or improved in 32 of 34 eyes (94%) over a 3-month follow-up interval.[69] Transient benign complications were apparent in 4 eyes. Only marginal improvement was shown in 4 eyes with no light perception vision; these were not analyzed with the remainder of the group.

CSF diversion procedures

CSF diversion procedures are highly effective in lowering ICP.[70] In some facilities, they remain the procedures of choice for treating IIH patients who do not respond to maximum medical treatment.[4, 6, 66] Shunts are also indicated for patients with intractable headaches, patients in regions where there is no access to a surgeon comfortable with optic nerve sheath fenestration, and patients in whom optic nerve sheath fenestration has failed.

Lumboperitoneal shunting is the traditional method for providing prompt reduction of ICP in patients with IIH.[71] However, this procedure has a high 1-year failure rate. Some neurosurgeons currently prefer ventriculoperitoneal or ventriculoatrial shunting to lumboperitoneal shunting.

The main reason why these neurosurgeons prefer ventricular shunts is that such shunts can be monitored for function by using an extracranial subcutaneous compressible bulb and a 1-way valve (permitting intracranial-to-abdominal flow) in series with the intracranial and abdominal ends of the shunt. The bulb will resist digital compression if the distal (abdominal or atrial) end is obstructed. It will collapse under digital pressure but will fail to reinflate if the intracranial end is obstructed.

Many neurosurgeons have been reluctant to place ventricular shunts in patients with IIH because the ventricles are small and difficult to cannulate without radiographic guidance. In addition, there is a significant risk of complications (eg, infection, stroke, seizures, and shunt failure). However, Woodworth et al reported that with a frameless stereotactic approach, they were able to place ventricular shunts in a single pass in all patients, even into slit ventricles, with good long-term viability.[72]

Sinclair et al found that although CSF diversion minimizes visual decline and improves visual acuity, 68% of patients continued to have headaches and 28% had low-pressure headaches that complicated surgery. Shunt revision was required for 51% of patients, with most requiring multiple revisions. For those with otherwise untreatable rapidly declining vision, CSF diversion shunting should be conducted as a last resort. Other treatments, such as weight reduction, may be more effective and may have less associated morbidity.[73]

Intracranial venous sinus stenting

Following up on the work of Farb et al, Bussière et al studied 13 patients with IIH that was refractory to medical management who were found to have stenosis of one or both of the transverse dural sinuses on time-of-flight magnetic resonance (MR) venography. Of these, 10 also had increased pressure gradient across the stenotic dural venous sinus (>10 mm Hg), and these underwent stent placement without significant complications.[74]

All 10 of the patients experienced complete resolution or significant improvement of their headaches, and 8 experienced complete or near-complete resolution of papilledema.[74] The authors suggested only that a randomized, controlled study of transverse dural venous sinus stenting in the management of IIH was needed to establish the safety and efficacy of the procedure in this setting.

Arac et al reported 1 case of endovascular stenting for IIH and reviewed the same published series that Bussière et al did, arriving at essentially the same conclusions.[75] They also discussed Bateman’s proposed mathematical model of the relations among intracranial arterial inflow, CSF pressure, and venous outflow (see Pathophysiology).

Comparison of visual outcomes

In a meta-analysis of the existing literature comparing visual outcomes after optic nerve sheath decompression, ventriculoperitoneal and lumboperitoneal shunting, and intracranial venous sinus stenting, Feldon reported the following findings[3] :

  • 252 optic nerve sheath decompressions – Visual defects were improved or resolved in 80%
  • 31 ventriculoperitoneal (VP) shunt placements – Visual defects were improved or resolved in 38.7%
  • 44 lumboperitoneal (LP) shunt placements – Visual defects were improved or resolved in 44.6%
  • 17 intracranial venous sinus stent placements – Visual defects were improved or resolved in 47%

Visual worsening was rare for all procedures. The author concluded that visual outcome was best documented for optic nerve sheath fenestration, which appeared to be the best surgical procedure for vision loss in IIH.


Bariatric Surgery

In a review of the literature on bariatric surgery for obese patients with IIH, Fridley et al found a total of 62 patients, of whom 52 (92%) experienced resolution of the presenting symptoms.[76] Of 35 patients who underwent postoperative funduscopy, 34 had resolution of papilledema. Of 12 patients who underwent pre- and postoperative visual field examinations, 11 showed resolution of visual field defects.

Among 13 patients in whom CSF pressures were measured pre- and postoperatively, there was an average postoperative decrease of 254 mm water.[76] The authors called for prospective controlled studies to confirm the effectiveness of this surgical approach for IIH patients in long-term follow-up.


Admission Criteria

Admission for pain management

Even for initial diagnosis, most patients do not require inpatient care, because lumbar puncture is usually performed in the ambulatory care setting. An occasional patient may develop an intractable low-tension headache after lumbar puncture and may require a short hospital stay for intravenous (IV) hydration and analgesic management. A blood patch (by an anesthesiologist) is sometimes indicated if the post–lumbar puncture headache does not subside spontaneously within a few days.

Admission for surgical management of increased ICP

Patients who complain of progressive visual loss (typically, constriction of peripheral vision or dimming of vision in one or both of the eyes) and have documented new visual field loss may respond to high-dose corticosteroid therapy; they should be admitted to the hospital and should undergo daily monitoring of visual function.

If the visual field worsens or does not recover promptly (ie, within 24-48 hours) with corticosteroid therapy, then emergency CSF shunting (lumboperitoneal, ventriculoperitoneal, or ventriculoatrial) or optic nerve sheath fenestration should be carried out.

If any delay in implementing surgical decompression of the failing optic nerve is anticipated, the patient should be moved to the intensive care unit (ICU) or a stepdown unit for lumbar CSF drainage until the definitive procedure can be performed. Another short-term treatment option is IV mannitol, but definitive pressure-lowering surgery must still be done within 2-3 days.

A very small number of patients with normal visual fields may require surgical relief of CSF pressure because of intractable headache. Optic nerve sheath fenestration does not provide reliable CSF pressure normalization or headache relief; thus, these patients will require a shunting procedure. Because patients with IIH frequently have other types of headaches, the decision to choose ventriculoperitoneal shunting over optic nerve sheath fenestration should not be made on the basis of headache alone.


Diet and Activity

Most patients with this disorder are females who are overweight. Weight loss is a cornerstone in the long-term management of these patients. As little as a 5-10% weight loss has been demonstrated to yield a reduction in ICP with accompanying resolution of papilledema.[49, 48, 2] Unfortunately, weight reduction generally proves to be a difficult task for these patients.[77] To formalize the process of weight reduction, referral to a dietitian is appropriate.

On initial diagnosis, a weight-reduction diet should be strongly recommended to all patients with IIH. Often, a formal weight-loss program is required. No activity restriction is required in managing IIH. In fact, exercise programs are strongly recommended in conjunction with the weight-reduction diet.



Diagnosis and long-term management of patients with IIH requires the performance of lumbar puncture, which is typically performed by neurologists or internists, and careful monitoring of visual status (in particular, peripheral visual field and fundus photography). Vision examination and fundus photography are the domain of ophthalmologists, and neuro-ophthalmologists are especially expert in examining visual fields. A team approach is therefore needed for most, if not all, patients.

Neurosurgical consultation is required for ventriculoperitoneal shunting when patients are losing visual field and medical management does not arrest or reverse the process promptly (ie, within hours to days). Consultation with an orbital plastic surgeon is required for optic nerve sheath fenestration for the same clinical indications.


Long-Term Monitoring

The frequency of the follow-up visits is determined by a number of factors, to include the following:

  • Initial visual function of the patient
  • Underlying disease causing increased ICP
  • Perceived compliance of the patient with medical therapy

Once the initial diagnosis has been established, investigations have been performed, and therapy has been initiated, the patient can be observed every 3-4 weeks.

If, however, the patient presents with a significant visual function deficit or marked papilledema, daily monitoring for 1 week is appropriate until some improvement and subsequent stability in visual function can be demonstrated. The clinician should be prepared to titrate the patient’s treatment to the status of visual function and should not hesitate to refer the patient for surgical treatment (optic nerve sheath fenestration or CSF diversion) visual function does not stabilize.

During follow-up visits, the best-corrected visual acuity for distant and near vision, color vision (with pseudoisochromatic plates), static perimetry, and optic nerve appearance (including the status of spontaneous venous pulsations) should be recorded. Patients who do not perform well on static perimetry testing may be better followed with kinetic perimetry testing.

Spontaneous pulsation of large retinal veins generally indicates a normal ICP. If the patient continues to remark on the persistence of a significant headache despite the presence of spontaneous venous pulsations, a source other than IIH for the headache should be considered.

When a patient appears to have stabilized with respect to visual function and treatment, the frequency of follow-up visits can be extended to once every 2-4 months.

Contributor Information and Disclosures

Mark S Gans, MD Associate Professor, Director of Neuro-Ophthalmology, Interim Chair, Department of Ophthalmology, McGill University Faculty of Medicine; Clinical Director, Department of Ophthalmology, Adult Sites, McGill University Hospital Center, Canada

Mark S Gans, MD is a member of the following medical societies: American Academy of Ophthalmology, Canadian Medical Association, North American Neuro-Ophthalmology Society, Canadian Ophthalmological Society

Disclosure: Nothing to disclose.

Chief Editor

Andrew G Lee, MD Chair, Department of Ophthalmology, Houston Methodist Hospital; Clinical Professor, Associate Program Director, Department of Ophthalmology and Visual Sciences, University of Texas Medical Branch School of Medicine; Clinical Professor, Department of Surgery, Division of Head and Neck Surgery, University of Texas MD Anderson Cancer Center; Professor of Ophthalmology, Neurology, and Neurological Surgery, Weill Medical College of Cornell University; Clinical Associate Professor, University of Buffalo, State University of New York School of Medicine

Andrew G Lee, MD is a member of the following medical societies: American Academy of Ophthalmology, Association of University Professors of Ophthalmology, American Geriatrics Society, Houston Neurological Society, Houston Ophthalmological Society, International Council of Ophthalmology, North American Neuro-Ophthalmology Society, Pan-American Association of Ophthalmology, Texas Ophthalmological Association

Disclosure: Received ownership interest from Credential Protection for other.


Robert A Egan, MD Director of Neuro-Ophthalmology, St Helena Hospital

Robert A Egan, MD is a member of the following medical societies: American Academy of Neurology, American Heart Association, North American Neuro-Ophthalmology Society, and Oregon Medical Association

Disclosure: Nothing to disclose.

Eric R Eggenberger, DO, MS, FAAN Professor, Vice-Chairman, Department of Neurology and Ophthalmology, Colleges of Osteopathic Medicine and Human Medicine, Michigan State University; Director of Michigan State University Ocular Motility Laboratory; Director of National Multiple Sclerosis Society Clinic, Michigan State University

Eric R Eggenberger, DO, MS, FAAN is a member of the following medical societies: American Academy of Neurology, American Academy of Ophthalmology, American Osteopathic Association, and North American Neuro-Ophthalmology Society

Disclosure: Nothing to disclose.

James Goodwin, MD Associate Professor, Departments of Neurology and Ophthalmology, University of Illinois College of Medicine; Director, Neuro-Ophthalmology Service, University of Illinois Eye and Ear Infirmary

James Goodwin, MD is a member of the following medical societies: American Academy of Neurology, Illinois State Medical Society, North American Neuro-Ophthalmology Society, and Royal Society of Medicine

Disclosure: Nothing to disclose.

Edsel Ing, MD, FRCSC Associate Professor, Department of Ophthalmology and Vision Sciences, University of Toronto Faculty of Medicine; Consulting Staff, Toronto East General Hospital, Canada

Edsel Ing, MD, FRCSC is a member of the following medical societies: American Academy of Ophthalmology, American Association for Pediatric Ophthalmology and Strabismus, American Society of Ophthalmic Plastic and Reconstructive Surgery, Canadian Ophthalmological Society, North American Neuro-Ophthalmology Society, and Royal College of Physicians and Surgeons of Canada

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Brian R Younge, MD Professor of Ophthalmology, Mayo Clinic School of Medicine

Brian R Younge, MD is a member of the following medical societies: American Medical Association, American Ophthalmological Society, and North American Neuro-Ophthalmology Society

Disclosure: Nothing to disclose.

  1. Jindal M, Hiam L, Raman A, Rejali D. Idiopathic intracranial hypertension in otolaryngology. Eur Arch Otorhinolaryngol. 2009 Jun. 266(6):803-6. [Medline].

  2. Wall M. Idiopathic intracranial hypertension (pseudotumor cerebri). Curr Neurol Neurosci Rep. 2008 Mar. 8(2):87-93. [Medline].

  3. Feldon SE. Visual outcomes comparing surgical techniques for management of severe idiopathic intracranial hypertension. Neurosurg Focus. 2007. 23(5):E6. [Medline].

  4. Friedman DI, Jacobson DM. Idiopathic intracranial hypertension. J Neuroophthalmol. 2004 Jun. 24(2):138-45. [Medline].

  5. Friedman DI, Jacobson DM. Diagnostic criteria for idiopathic intracranial hypertension. Neurology. 2002 Nov 26. 59(10):1492-5. [Medline].

  6. Miller NR, Newman NJ. Pseudotumor cerebri (benign intracranial hypertension). In:. Walsh and Hoyt’s Clinical Neuro-Ophthalmology. Vol 1. 5th ed. 1999:523-38.:

  7. Bateman GA, Stevens SA, Stimpson J. A mathematical model of idiopathic intracranial hypertension incorporating increased arterial inflow and variable venous outflow collapsibility. J Neurosurg. 2009 Mar. 110(3):446-56. [Medline].

  8. Farb RI, Vanek I, Scott JN, Mikulis DJ, Willinsky RA, Tomlinson G, et al. Idiopathic intracranial hypertension: the prevalence and morphology of sinovenous stenosis. Neurology. 2003 May 13. 60(9):1418-24. [Medline].

  9. Bateman GA. Association between arterial inflow and venous outflow in idiopathic and secondary intracranial hypertension. J Clin Neurosci. 2006 Jun. 13(5):550-6; discussion 557. [Medline].

  10. Bateman GA. Arterial inflow and venous outflow in idiopathic intracranial hypertension associated with venous outflow stenoses. J Clin Neurosci. 2008 Apr. 15(4):402-8. [Medline].

  11. Corbett JJ. The first Jacobson Lecture. Familial idiopathic intracranial hypertension. J Neuroophthalmol. 2008 Dec. 28(4):337-47. [Medline].

  12. Daniels AB, Liu GT, Volpe NJ, Galetta SL, Moster ML, Newman NJ, et al. Profiles of obesity, weight gain, and quality of life in idiopathic intracranial hypertension (pseudotumor cerebri). Am J Ophthalmol. 2007 Apr. 143(4):635-41. [Medline].

  13. Radhakrishnan K, Ahlskog JE, Garrity JA, Kurland LT. Idiopathic intracranial hypertension. Mayo Clin Proc. 1994 Feb. 69(2):169-80. [Medline].

  14. Rogers AH, Rogers GL, Bremer DL, McGregor ML. Pseudotumor cerebri in children receiving recombinant human growth hormone. Ophthalmology. 1999 Jun. 106(6):1186-9; discussion 1189-90. [Medline].

  15. Howell SJ, Wilton P, Shalet SM. Growth hormone replacement in patients with Langerhan's cell histiocytosis. Arch Dis Child. 1998 May. 78(5):469-73. [Medline]. [Full Text].

  16. Crock PA, McKenzie JD, Nicoll AM, Howard NJ, Cutfield W, Shield LK, et al. Benign intracranial hypertension and recombinant growth hormone therapy in Australia and New Zealand. Acta Paediatr. 1998 Apr. 87(4):381-6. [Medline].

  17. Williams JB. Adverse effects of thyroid hormones. Drugs Aging. 1997 Dec. 11(6):460-9. [Medline].

  18. Raghavan S, DiMartino-Nardi J, Saenger P, Linder B. Pseudotumor cerebri in an infant after L-thyroxine therapy for transient neonatal hypothyroidism. J Pediatr. 1997 Mar. 130(3):478-80. [Medline].

  19. Sacchi S, Russo D, Avvisati G, Dastoli G, Lazzarino M, Pelicci PG, et al. All-trans retinoic acid in hematological malignancies, an update. GER (Gruppo Ematologico Retinoidi). Haematologica. 1997 Jan-Feb. 82(1):106-21. [Medline].

  20. Visani G, Bontempo G, Manfroi S, Pazzaglia A, D'Alessandro R, Tura S. All-trans-retinoic acid and pseudotumor cerebri in a young adult with acute promyelocytic leukemia: a possible disease association. Haematologica. 1996 Mar-Apr. 81(2):152-4. [Medline].

  21. Selleri C, Pane F, Notaro R, Catalano L, Santoro LE, Luciano L, et al. All-trans-retinoic acid (ATRA) responsive skin relapses of acute promyelocytic leukaemia followed by ATRA-induced pseudotumour cerebri. Br J Haematol. 1996 Mar. 92(4):937-40. [Medline].

  22. Ahmad S. Amiodarone and reversible benign intracranial hypertension. Cardiology. 1996 Jan-Feb. 87(1):90. [Medline].

  23. Varadi G, Lossos A, Or R, Kapelushnik J, Nagler A. Successful allogeneic bone marrow transplantation in a patient with ATRA-induced pseudotumor cerebri. Am J Hematol. 1995 Oct. 50(2):147-8. [Medline].

  24. Sivin I. Serious adverse events in Norplant users reported to the Food and Drug Administration's MedWatch Spontaneous Reporting System. Obstet Gynecol. 1995 Aug. 86(2):318-20. [Medline].

  25. Baqui AH, de Francisco A, Arifeen SE, Siddique AK, Sack RB. Bulging fontanelle after supplementation with 25,000 IU of vitamin A in infancy using immunization contacts. Acta Paediatr. 1995 Aug. 84(8):863-6. [Medline].

  26. Alder JB, Fraunfelder FT, Edwards R. Levonorgestrel implants and intracranial hypertension. N Engl J Med. 1995 Jun 22. 332(25):1720-1. [Medline].

  27. Malozowski S, Tanner LA, Wysowski DK, Fleming GA, Stadel BV. Benign intracranial hypertension in children with growth hormone deficiency treated with growth hormone. J Pediatr. 1995 Jun. 126(6):996-9. [Medline].

  28. Campos SP, Olitsky S. Idiopathic intracranial hypertension after L-thyroxine therapy for acquired primary hypothyroidism. Clin Pediatr (Phila). 1995 Jun. 34(6):334-7. [Medline].

  29. Nasr SZ, Schaffert D. Symptomatic increase in intracranial pressure following pancreatic enzyme replacement therapy for cystic fibrosis. Pediatr Pulmonol. 1995 Jun. 19(6):396-7. [Medline].

  30. Price DA, Clayton PE, Lloyd IC. Benign intracranial hypertension induced by growth hormone treatment. Lancet. 1995 Feb 18. 345(8947):458-9. [Medline].

  31. Kelly SJ, O'Donnell T, Fleming JC, Einhaus S. Pseudotumor cerebri associated with lithium use in an 11-year-old boy. J AAPOS. 2009 Apr. 13(2):204-6. [Medline].

  32. Mollan SP, Ball AK, Sinclair AJ, Madill SA, Clarke CE, Jacks AS, et al. Idiopathic intracranial hypertension associated with iron deficiency anaemia: a lesson for management. Eur Neurol. 2009. 62(2):105-8. [Medline].

  33. Lin A, Foroozan R, Danesh-Meyer HV, De Salvo G, Savino PJ, Sergott RC. Occurrence of cerebral venous sinus thrombosis in patients with presumed idiopathic intracranial hypertension. Ophthalmology. 2006 Dec. 113(12):2281-4. [Medline].

  34. Kesler A, Yatziv Y, Shapira I, Berliner S, Assayag EB. Increased red blood cell aggregation in patients with idiopathic intracranial hypertension. A hitherto unexplored pathophysiological pathway. Thromb Haemost. 2006 Oct. 96(4):483-7. [Medline].

  35. Warner JE, Larson AJ, Bhosale P, Digre KB, Henley C, Alder SC, et al. Retinol-binding protein and retinol analysis in cerebrospinal fluid and serum of patients with and without idiopathic intracranial hypertension. J Neuroophthalmol. 2007 Dec. 27(4):258-62. [Medline].

  36. Fraser JA, Bruce BB, Rucker J, Fraser LA, Atkins EJ, Newman NJ, et al. Risk factors for idiopathic intracranial hypertension in men: a case-control study. J Neurol Sci. 2010 Mar 15. 290(1-2):86-9. [Medline]. [Full Text].

  37. Durcan FJ, Corbett JJ, Wall M. The incidence of pseudotumor cerebri. Population studies in Iowa and Louisiana. Arch Neurol. 1988 Aug. 45(8):875-7. [Medline].

  38. Radhakrishnan K, Ahlskog JE, Cross SA, Kurland LT, O'Fallon WM. Idiopathic intracranial hypertension (pseudotumor cerebri). Descriptive epidemiology in Rochester, Minn, 1976 to 1990. Arch Neurol. 1993 Jan. 50(1):78-80. [Medline].

  39. Radhakrishnan K, Thacker AK, Bohlaga NH, Maloo JC, Gerryo SE. Epidemiology of idiopathic intracranial hypertension: a prospective and case-control study. J Neurol Sci. 1993 May. 116(1):18-28. [Medline].

  40. Jirásková N, Rozsíval P. Idiopathic intracranial hypertension in pediatric patients. Clin Ophthalmol. 2008 Dec. 2(4):723-6. [Medline]. [Full Text].

  41. Bruce BB, Kedar S, Van Stavern GP, Monaghan D, Acierno MD, Braswell RA, et al. Idiopathic intracranial hypertension in men. Neurology. 2009 Jan 27. 72(4):304-9. [Medline]. [Full Text].

  42. Digre KB, Nakamoto BK, Warner JE, Langeberg WJ, Baggaley SK, Katz BJ. A comparison of idiopathic intracranial hypertension with and without papilledema. Headache. 2009 Feb. 49(2):185-93. [Medline].

  43. Corbett JJ, Savino PJ, Thompson HS, Kansu T, Schatz NJ, Orr LS, et al. Visual loss in pseudotumor cerebri. Follow-up of 57 patients from five to 41 years and a profile of 14 patients with permanent severe visual loss. Arch Neurol. 1982 Aug. 39(8):461-74. [Medline].

  44. Agostoni E, Aliprandi A. Alterations in the cerebral venous circulation as a cause of headache. Neurol Sci. 2009 May. 30 Suppl 1:S7-10. [Medline].

  45. Ney JJ, Volpe NJ, Liu GT, Balcer LJ, Moster ML, Galetta SL. Functional visual loss in idiopathic intracranial hypertension. Ophthalmology. 2009 Sep. 116(9):1808-1813.e1. [Medline].

  46. Wall M, George D. Visual loss in pseudotumor cerebri. Incidence and defects related to visual field strategy. Arch Neurol. 1987 Feb. 44(2):170-5. [Medline].

  47. Shah VA, Kardon RH, Lee AG, Corbett JJ, Wall M. Long-term follow-up of idiopathic intracranial hypertension: the Iowa experience. Neurology. 2008 Feb 19. 70(8):634-40. [Medline].

  48. Kupersmith MJ, Gamell L, Turbin R, Peck V, Spiegel P, Wall M. Effects of weight loss on the course of idiopathic intracranial hypertension in women. Neurology. 1998 Apr. 50(4):1094-8. [Medline].

  49. Rowe FJ, Sarkies NJ. Assessment of visual function in idiopathic intracranial hypertension: a prospective study. Eye (Lond). 1998. 12 ( Pt 1):111-8. [Medline].

  50. Sugerman HJ, Felton WL 3rd, Salvant JB Jr, Sismanis A, Kellum JM. Effects of surgically induced weight loss on idiopathic intracranial hypertension in morbid obesity. Neurology. 1995 Sep. 45(9):1655-9. [Medline].

  51. Sugerman HJ, Felton WL 3rd, Sismanis A, Kellum JM, DeMaria EJ, Sugerman EL. Gastric surgery for pseudotumor cerebri associated with severe obesity. Ann Surg. 1999 May. 229(5):634-40; discussion 640-2. [Medline]. [Full Text].

  52. González-Hernández A, Fabre-Pi O, Díaz-Nicolás S, López-Fernández JC, López-Veloso C, Jiménez-Mateos A. [Headache in idiopathic intracranial hypertension]. Rev Neurol. 2009 Jul 1-15. 49(1):17-20. [Medline].

  53. Nampoory MR, Johny KV, Gupta RK, Constandi JN, Nair MP, al-Muzeiri I. Treatable intracranial hypertension in patients with lupus nephritis. Lupus. 1997. 6(7):597-602. [Medline].

  54. Leker RR, Steiner I. Anticardiolipin antibodies are frequently present in patients with idiopathic intracranial hypertension. Arch Neurol. 1998 Jun. 55(6):817-20. [Medline].

  55. Sussman J, Leach M, Greaves M, Malia R, Davies-Jones GA. Potentially prothrombotic abnormalities of coagulation in benign intracranial hypertension. J Neurol Neurosurg Psychiatry. 1997 Mar. 62(3):229-33. [Medline]. [Full Text].

  56. Bachman DT, Srivastava G. Emergency department presentations of Lyme disease in children. Pediatr Emerg Care. 1998 Oct. 14(5):356-61. [Medline].

  57. Agid R, Farb RI, Willinsky RA, Mikulis DJ, Tomlinson G. Idiopathic intracranial hypertension: the validity of cross-sectional neuroimaging signs. Neuroradiology. 2006 Aug. 48(8):521-7. [Medline].

  58. Maralani PJ, Hassanlou M, Torres C, Chakraborty S, Kingstone M, Patel V, et al. Accuracy of brain imaging in the diagnosis of idiopathic intracranial hypertension. Clin Radiol. 2012 Jul. 67(7):656-63. [Medline].

  59. Stone MB. Ultrasound diagnosis of papilledema and increased intracranial pressure in pseudotumor cerebri. Am J Emerg Med. 2009 Mar. 27(3):376.e1-376.e2. [Medline].

  60. Szewka AJ, Bruce BB, Newman NJ, Biousse V. Idiopathic Intracranial Hypertension: Relation Between Obesity and Visual Outcomes. J Neuroophthalmol. 2012 Jan 3. [Medline]. [Full Text].

  61. Digre KB, Varner MW, Corbett JJ. Pseudotumor cerebri and pregnancy. Neurology. 1984 Jun. 34(6):721-9. [Medline].

  62. Giuseffi V, Wall M, Siegel PZ, Rojas PB. Symptoms and disease associations in idiopathic intracranial hypertension (pseudotumor cerebri): a case-control study. Neurology. 1991 Feb. 41(2 ( Pt 1)):239-44. [Medline].

  63. Hughes S. Drug Improves Vision in Idiopathic Intracranial Hypertension. Medscape Medical News. Available at Accessed: April 29, 2014.

  64. Wall M, McDermott MP, Kieburtz KD, Corbett JJ, Feldon SE, Friedman DI, et al. Effect of acetazolamide on visual function in patients with idiopathic intracranial hypertension and mild visual loss: the idiopathic intracranial hypertension treatment trial. JAMA. 2014 Apr 23-30. 311(16):1641-51. [Medline].

  65. Goh KY, Schatz NJ, Glaser JS. Optic nerve sheath fenestration for pseudotumor cerebri. J Neuroophthalmol. 1997 Jun. 17(2):86-91. [Medline].

  66. Brazis PW. Clinical review: the surgical treatment of idiopathic pseudotumour cerebri (idiopathic intracranial hypertension). Cephalalgia. 2008 Dec. 28(12):1361-73. [Medline].

  67. Chandrasekaran S, McCluskey P, Minassian D, Assaad N. Visual outcomes for optic nerve sheath fenestration in pseudotumour cerebri and related conditions. Clin Experiment Ophthalmol. 2006 Sep-Oct. 34(7):661-5. [Medline].

  68. Spoor TC, McHenry JG. Long-term effectiveness of optic nerve sheath decompression for pseudotumor cerebri. Arch Ophthalmol. 1993 May. 111(5):632-5. [Medline].

  69. Nithyanandam S, Manayath GJ, Battu RR. Optic nerve sheath decompression for visual loss in intracranial hypertension: report from a tertiary care center in South India. Indian J Ophthalmol. 2008 Mar-Apr. 56(2):115-20. [Medline]. [Full Text].

  70. Yadav YR, Parihar V, Agarwal M, Bhatele PR, Saxena N. Lumbar peritoneal shunt in idiopathic intracranial hypertension. Turk Neurosurg. 2012. 22(1):21-6. [Medline].

  71. Burgett RA, Purvin VA, Kawasaki A. Lumboperitoneal shunting for pseudotumor cerebri. Neurology. 1997 Sep. 49(3):734-9. [Medline].

  72. Woodworth GF, McGirt MJ, Elfert P, Sciubba DM, Rigamonti D. Frameless stereotactic ventricular shunt placement for idiopathic intracranial hypertension. Stereotact Funct Neurosurg. 2005. 83(1):12-6. [Medline].

  73. Sinclair AJ, Kuruvath S, Sen D, Nightingale PG, Burdon MA, Flint G. Is cerebrospinal fluid shunting in idiopathic intracranial hypertension worthwhile? A 10-year review. Cephalalgia. 2011 Dec. 31(16):1627-33. [Medline].

  74. Bussière M, Falero R, Nicolle D, Proulx A, Patel V, Pelz D. Unilateral transverse sinus stenting of patients with idiopathic intracranial hypertension. AJNR Am J Neuroradiol. 2010 Apr. 31(4):645-50. [Medline].

  75. Arac A, Lee M, Steinberg GK, Marcellus M, Marks MP. Efficacy of endovascular stenting in dural venous sinus stenosis for the treatment of idiopathic intracranial hypertension. Neurosurg Focus. 2009 Nov. 27(5):E14. [Medline].

  76. Fridley J, Foroozan R, Sherman V, Brandt ML, Yoshor D. Bariatric surgery for the treatment of idiopathic intracranial hypertension. J Neurosurg. 2011 Jan. 114(1):34-9. [Medline].

  77. Johnson LN, Krohel GB, Madsen RW, March GA Jr. The role of weight loss and acetazolamide in the treatment of idiopathic intracranial hypertension (pseudotumor cerebri). Ophthalmology. 1998 Dec. 105(12):2313-7. [Medline].

  78. Pollak L, Zohar E, Glovinsky Y, Huna-Baron R. Reevaluation of presentation and course of idiopathic intracranial hypertension - a large cohort comprehensive study. Acta Neurol Scand. 2012 Dec 31. [Medline].

Left optic disc with moderate chronic papilledema in a patient with idiopathic intracranial hypertension (pseudotumor cerebri). Paton lines (arc-shaped retinal wrinkles concentric with the disc margin) are seen along the temporal side of the optic nerve head.
Right optic disc with postpapilledema optic atrophy in a patient with idiopathic intracranial hypertension (pseudotumor cerebri). Diffuse pallor of disc and absence of small arterial vessels on surface are noted, with very little disc elevation. Disc margin at upper and lower poles and nasally is obscured by some residual edema in nerve fiber layer and gliosis that often persists even after all edema has resolved.
Most common early visual field defect in papilledema as optic nerve develops optic atrophy is inferior nasal defect, as shown in left eye field chart (left side of figure). Shaded area indicates defective portion of field. Note sharp line of demarcation between defective lower nasal quadrant and normal upper nasal quadrant along horizontal midline. This is characteristic of early papilledema optic atrophy and is referred to as nasal step or inferonasal step.
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.